Research ExplorerPublicationsLeptomeningeal Carcinomatosis: A Clinical Dilemma in Neuroen...

Leptomeningeal Carcinomatosis: A Clinical Dilemma in Neuroendocrine Neoplasms

Standard

Leptomeningeal Carcinomatosis: A Clinical Dilemma in Neuroendocrine Neoplasms. / Apostolidis, Leonidas; Schrader, Jörg; Jann, Henning; Rinke, Anja; Krug, Sebastian.

In: BIOLOGY-BASEL, Vol. 10, No. 4, 277, 28.03.2021.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Apostolidis, L, Schrader, J, Jann, H, Rinke, A & Krug, S 2021, 'Leptomeningeal Carcinomatosis: A Clinical Dilemma in Neuroendocrine Neoplasms', BIOLOGY-BASEL, vol. 10, no. 4, 277. https://doi.org/10.3390/biology10040277

APA

Apostolidis, L., Schrader, J., Jann, H., Rinke, A., & Krug, S. (2021). Leptomeningeal Carcinomatosis: A Clinical Dilemma in Neuroendocrine Neoplasms. BIOLOGY-BASEL, 10(4), [277]. https://doi.org/10.3390/biology10040277

Vancouver

Apostolidis L, Schrader J, Jann H, Rinke A, Krug S. Leptomeningeal Carcinomatosis: A Clinical Dilemma in Neuroendocrine Neoplasms. BIOLOGY-BASEL. 2021 Mar 28;10(4). 277. https://doi.org/10.3390/biology10040277

Bibtex

@article{bbea399b77d940b3ba930664071caff4,
title = "Leptomeningeal Carcinomatosis: A Clinical Dilemma in Neuroendocrine Neoplasms",
abstract = "Central nervous system (CNS) involvement by paraneoplastic syndromes, brain metastases, or leptomeningeal carcinomatosis (LC) in patients with neuroendocrine neoplasms (NEN) has only been described in individual case reports. We evaluated patients with LC in four neuroendocrine tumor (NET) centers (Halle/Saale, Hamburg, Heidelberg, and Marburg) and characterized them clinically. In the study, 17 patients with a LC were defined with respect to diagnosis, clinic, and therapy. The prognosis of a LC is very poor, with 10 months in median overall survival (mOS). This is reflected by an even worse course in neuroendocrine carcinoma (NEC) G3 Ki-67 >55%, with a mOS of 2 months. Motor and sensory deficits together with vigilance abnormalities were common symptoms. In most cases, targeted radiation or temozolomide therapy was used against the LC. LC appears to be similarly devastating to brain metastases in NEN patients. Therefore, the indication for CNS imaging should be discussed in certain cases.",
author = "Leonidas Apostolidis and J{\"o}rg Schrader and Henning Jann and Anja Rinke and Sebastian Krug",
year = "2021",
month = mar,
day = "28",
doi = "10.3390/biology10040277",
language = "English",
volume = "10",
journal = "BIOLOGY-BASEL",
issn = "2079-7737",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "4",

}

RIS

TY - JOUR

T1 - Leptomeningeal Carcinomatosis: A Clinical Dilemma in Neuroendocrine Neoplasms

AU - Apostolidis, Leonidas

AU - Schrader, Jörg

AU - Jann, Henning

AU - Rinke, Anja

AU - Krug, Sebastian

PY - 2021/3/28

Y1 - 2021/3/28

N2 - Central nervous system (CNS) involvement by paraneoplastic syndromes, brain metastases, or leptomeningeal carcinomatosis (LC) in patients with neuroendocrine neoplasms (NEN) has only been described in individual case reports. We evaluated patients with LC in four neuroendocrine tumor (NET) centers (Halle/Saale, Hamburg, Heidelberg, and Marburg) and characterized them clinically. In the study, 17 patients with a LC were defined with respect to diagnosis, clinic, and therapy. The prognosis of a LC is very poor, with 10 months in median overall survival (mOS). This is reflected by an even worse course in neuroendocrine carcinoma (NEC) G3 Ki-67 >55%, with a mOS of 2 months. Motor and sensory deficits together with vigilance abnormalities were common symptoms. In most cases, targeted radiation or temozolomide therapy was used against the LC. LC appears to be similarly devastating to brain metastases in NEN patients. Therefore, the indication for CNS imaging should be discussed in certain cases.

AB - Central nervous system (CNS) involvement by paraneoplastic syndromes, brain metastases, or leptomeningeal carcinomatosis (LC) in patients with neuroendocrine neoplasms (NEN) has only been described in individual case reports. We evaluated patients with LC in four neuroendocrine tumor (NET) centers (Halle/Saale, Hamburg, Heidelberg, and Marburg) and characterized them clinically. In the study, 17 patients with a LC were defined with respect to diagnosis, clinic, and therapy. The prognosis of a LC is very poor, with 10 months in median overall survival (mOS). This is reflected by an even worse course in neuroendocrine carcinoma (NEC) G3 Ki-67 >55%, with a mOS of 2 months. Motor and sensory deficits together with vigilance abnormalities were common symptoms. In most cases, targeted radiation or temozolomide therapy was used against the LC. LC appears to be similarly devastating to brain metastases in NEN patients. Therefore, the indication for CNS imaging should be discussed in certain cases.

U2 - 10.3390/biology10040277

DO - 10.3390/biology10040277

M3 - SCORING: Journal article

C2 - 33800581

VL - 10

JO - BIOLOGY-BASEL

JF - BIOLOGY-BASEL

SN - 2079-7737

IS - 4

M1 - 277

ER -